Diabetes Mellitus, Type 2 Clinical Trial
Official title:
A Prospective, Randomized, Controlled Trial Comparing Cytal Wound Matrix 1-Layer to Standard of Care (SOC) in the Management of Diabetic Foot Ulcers (DFUs)
Verified date | August 2021 |
Source | Integra LifeSciences Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a two-armed randomized controlled trial (RCT) primarily aimed at determining if application of Cytal Wound Matrix 1-Layer intervention to diabetic foot ulcers shows improved wound closure rates when compared to standard care intervention.
Status | Terminated |
Enrollment | 15 |
Est. completion date | February 18, 2020 |
Est. primary completion date | February 18, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility | Inclusion Criteria: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Provision of signed and dated informed consent form by subject or legally authorized representative. 2. Stated willingness to comply with all study procedures and availability for the duration of the study. Subject is able and willing to tolerate non-removable offloading device for the duration of the run-in and intervention phases of the study. 3. Subject is male or female and at least 21years of age. 4. Subject has a clinical diagnosis of type 1 or type 2 diabetes. 5. Subject's current foot ulcer(s) has been present for > 30 days and = 365 days. 6. Subject's current foot ulcer(s), post-debridement is/are predominantly below the malleoli and on the plantar surface of the foot. 7. Subject's foot ulcer(s) must be Wagner type 1 or type 2. 8. Post debridement, subject's ulcer(s) are free of necrotic debris and appear to be comprised of healthy, vascularized tissue. 9. All qualifying ulcers are = 5cm away from any other ulcer on the same foot. 10. Subject's ulcer(s) is = 1cm2 and = 20cm2 at randomization (length x width). 11. Subject's HbA1C reading is =10%. 12. Subject's Serum Creatinine = 3.0mg/dL. 13. Subject has adequate circulation to the foot as measured by Ankle-Brachial Index (ABI) = 0.7. 14. Negative pregnancy test at randomization for women. Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Subject is pregnant, breastfeeding, or unwilling to practice birth control during participation in the study, if applicable. 2. Allergy or hypersensitivity to materials in porcine-based study products (per subject report) or personal preference. 3. Subject report of concurrent participation in another clinical trial that involves a drug. 4. The subject has any condition that, in the Investigator's opinion, would warrant exclusion from the study or prevent the subject from completing the study. 5. Subject has clinical evidence of gangrene on any part of the affected foot. 6. The subject's ulcer(s) is/are due to a non-diabetic etiology, ulcers of arterial, venous stasis, pressure, radiation, traumatic, rheumatoid, vasculitis, collagen vascular disease, or other non-diabetic etiologies. 7. Subject has unstable Charcot foot, Charcot foot with a bony prominence(s) or Charcot amputation. 8. Qualifying wound(s) is connected to another ulcer via a fistula. 9. Subject has one or more medical condition(s) including: renal, hepatic, hematological, neurologic, or immune disease that in the opinion of the Investigator would make the subject an inappropriate candidate for this wound healing study. 10. Subject has or has had a malignant disease (other than basal cell carcinoma) that has not been in remission for at least five years. 11. Subject is receiving oral or parenteral corticosteroids, immunosuppressive or cytotoxic agents, or is anticipated to require such during the course of the study. 12. Subject has acute osteomyelitis of the affected foot. 13. Subject's ulcer(s) is accompanied by active cellulitis. 14. Subject has received growth factor or enzymatic therapy within 2 weeks of consent. 15. Subject is currently receiving or has received radiation, radiologic implants, or chemotherapy. 16. Subject is allergic to any of the primary or secondary dressing materials, including occlusive dressings and the adhesives on such dressings. 17. Subject's ulcer(s) has decreased in size by >30% during the run-in phase. 18. Subject's ulcer(s) has increased in size by >50% during the run-in phase. 19. Subject's ulcer(s) has tunnels or sinus tracts that cannot be completely debrided. 20. Subject has severe malnutrition as evidenced by albumin <2.0 g/dL. 21. Subject has a bleeding disorder as documented by a diagnosis of a bleeding disorder. 22. Subject is on dialysis. 23. Any DFU(s) is infected and has not been treated for any clinically suspected infection prior to application of any product. |
Country | Name | City | State |
---|---|---|---|
United States | Limb Preservation Platform, Inc. | Fresno | California |
United States | MedStar Health Research Institute | Hyattsville | Maryland |
United States | Louisiana State University Health Science Center (LSUHSC) | New Orleans | Louisiana |
Lead Sponsor | Collaborator |
---|---|
Integra LifeSciences Corporation |
United States,
Bann CM, Fehnel SE, Gagnon DD. Development and validation of the Diabetic Foot Ulcer Scale-short form (DFS-SF). Pharmacoeconomics. 2003;21(17):1277-90. — View Citation
Chen YH, DeMets DL, Lan KK. Increasing the sample size when the unblinded interim result is promising. Stat Med. 2004 Apr 15;23(7):1023-38. — View Citation
Dumville JC, O'Meara S, Deshpande S, Speak K. Hydrogel dressings for healing diabetic foot ulcers. Cochrane Database Syst Rev. 2013 Jul 12;(7):CD009101. doi: 10.1002/14651858.CD009101.pub3. Review. — View Citation
Margolis DJ, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care. 1999 May;22(5):692-5. — View Citation
Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB. Burden of diabetic foot ulcers for medicare and private insurers. Diabetes Care. 2014;37(3):651-8. doi: 10.2337/dc13-2176. Epub 2013 Nov 1. Erratum in: Diabetes Care. 2014 Sep;37(9):2660. — View Citation
Wu L, Norman G, Dumville JC, O'Meara S, Bell-Syer SE. Dressings for treating foot ulcers in people with diabetes: an overview of systematic reviews. Cochrane Database Syst Rev. 2015 Jul 14;(7):CD010471. doi: 10.1002/14651858.CD010471.pub2. Review. — View Citation
Yazdanpanah L, Nasiri M, Adarvishi S. Literature review on the management of diabetic foot ulcer. World J Diabetes. 2015 Feb 15;6(1):37-53. doi: 10.4239/wjd.v6.i1.37. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Wounds With Wound Closure | The primary endpoint of the study is to measure the incidence of complete wound closure (defined as 100% epithelialization) between randomized groups. Number of wounds was calculated as the total across all participants. | up to 12 weeks | |
Secondary | Wound Size Change | Measure changes in wound size, measured in cm2/week between randomized groups. | up to 12 weeks | |
Secondary | Complete Wound Closure Time | Measure time to complete wound closure between randomized groups. | up to 12 weeks | |
Secondary | Wound Recurrence | Measure wound recurrence after healing is complete between randomized groups. | at 26 week visit and 52 week visit | |
Secondary | Short Form-20 (SF-20) | The Short Form-20 is a 20-item questionnaire used to assess generic health outcomes from the participant's perspective. Scores are linearly measured from 0 (worst) to 100 (best) health functioning scores, respectively. | Baseline visit, visit #7, visit #13, 26 wk. visit, and 52 wk.visit | |
Secondary | Diabetic Foot Ulcer Scale- Short Form (DFS-SF) | The diabetic foot ulcer scale- short form (DFS-SF) is a 29-item questionnaire designed to assess the impact of diabetic foot ulcers (DFUs) and their intervention on quality of life of participants diagnosed with diabetes. Scores measured from 0 (lower) to 100 (higher) quality of life, respectively. | Baseline visit, 26 week visit, and 52 week visit | |
Secondary | Visual Analogue Scale (VAS) for Pain | The visual analogue scale (VAS) is a psychometric response scale for pain. It measures subjective characteristics or attitudes regarding perceived pain levels from participants. Participants are asked to draw a vertical line on a 10 cm horizontal line indicating what their current pain level would be. The distance between the start of the horizontal line to the vertical line is calculated in cm with a higher score (100) indicating greater pain intensity. | Up to 52 week visit (until study completion) | |
Secondary | Katz Index of Independence in Activities of Daily Living (KATZ ADL) | The Katz ADL is a 6-item questionnaire measuring independence in activities of daily living such as bathing, dressing, toileting, transfers, feeding, and continence. Each item is dichotomized as either having a score of zero (i.e. dependence) or one (i.e. independence). This will be completed with the aid of a trained study staff member. | Baseline visit, visit 7, visit 13, 26 wk visit, and 52 wk visit | |
Secondary | Adverse Events Frequency | This outcome measures diabetic foot ulcer (DFU) related adverse event frequency including unexpected adverse device events (UADEs) or serious adverse experiences (SAEs) throughout the duration of the study as well as evaluate such adverse event frequencies between randomized groups. | up to 52 week visit (until study completion) | |
Secondary | Narcotic Prescription Changes Between Trial Arms | This outcome measures changes in number of diabetic foot ulcer (DFU) related narcotic prescriptions by study participant and between randomized groups. | up to 52 week visit (until study completion) | |
Secondary | Participant Ambulatory Status | This outcome measures any changes in ambulatory status (i.e. bed, wheel chair, walk w/ assistance, or walk independent) by study participant and between randomized groups. | up to 52 week visit (until study completion) | |
Secondary | Return to Work Status | This outcome measures differences in "return to work status" and/or "reported work status", activities of daily living, or disability status by study participant and between randomized groups. | up to 52 week visit (until study completion) | |
Secondary | Diabetic Foot Ulcer (DFU) Specific Ancillary Medical Care | This outcome measures the incidence of diabetic foot ulcer (DFU) specific related medical care a study participant receives outside of the medical care provided by the investigator. Examples of ancillary care include, but are not limited to, emergency room (ER) visits, urgent care visits, outside medical procedures such as surgery, etc. The incidence of subjects requiring ancillary medical care will be tabulated and compared between randomized groups. This data will be collected via two questions (i.e. "Did participant receive any ancillary medical care?" and "If "yes", then specify where"). Responses are verified using source documentation. | up to 52 week visit (until study completion) | |
Secondary | Diabetic Foot Ulcer (DFU) Related Direct Product(s) Costs | This outcome measures direct costs of the products by total cost per subject stratified by healed vs. non healed DFU. | up to 52 week visit (until study completion) | |
Secondary | Indirect Diabetic Foot Ulcer (DFU) Product(s) Costs | This outcome measures total indirect and incidental costs of diabetic foot ulcer products used per study participant by each visit. | up to 52 week visit (until study completion) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |